bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 396,800 shares, a decrease of 7.2% from the January 15th total of 427,500 shares. Approximately 4.2% of the company’s shares are short sold. Based on an average daily volume of 172,600 shares, the short-interest ratio is currently 2.3 days.
Institutional Inflows and Outflows
An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC increased its holdings in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) by 131.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,304 shares of the company’s stock after purchasing an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.64% of the company’s stock.
bioAffinity Technologies Trading Up 0.6 %
Shares of BIAF traded up $0.01 on Monday, hitting $0.81. 42,286 shares of the stock traded hands, compared to its average volume of 298,197. bioAffinity Technologies has a 1 year low of $0.57 and a 1 year high of $3.62. The stock’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.33. The firm has a market capitalization of $12.55 million, a P/E ratio of -0.98 and a beta of 2.95. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18.
About bioAffinity Technologies
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Featured Articles
- Five stocks we like better than bioAffinity Technologies
- How to Use the MarketBeat Stock Screener
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- How to Capture the Benefits of Dividend Increases
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
